Europe

Europe Focus Areas

Torreya Partners houses 10 professionals at our European office in London. We call on and advise life sciences clients across Europe. We are focused on the following areas:

Pharmaceuticals

We are a leading advisor of large and specialty pharmaceutical companies in North America with particularly heavy involvement in commercial-stage asset deals and M&A transactions. MORE »

Biotechnology

We work extensively with development stage biotechnology companies and assist in partnering advisory, M&A and financings. MORE »

Nutritionals / OTC

We have been involved with a number of leading companies in the nutritionals and medical foods areas having helped to complete more than $400 million of financings, alliances and other strategic transactions in this area. MORE »

Generic Pharma

We are heavily involved in transactions in the generic pharmaceutical sector and have recently worked on projects involving orals, liquids, manufacturing, transdermals and complex formulations. MORE »

Life Science Tools

We have extensive experience in the life science tools sector. One of our principals formerly ran Biowhittaker, a leading player in this space. MORE »

Medical Devices

We work extensively with development stage biotechnology companies and assist in partnering advisory, M&A and financings. MORE »

Diagnostics

We are very active in diagnostics working on projects in the area of automated histopathology, automated microscopy, genome sequencing and RNA-based diagnostics. MORE »

Selected Past Deals

Midatech Pharma

Acquisition of Dara Biosciences

Up to $30 million

June 2015

Europe

arGEN-X

License of a preclinical antibody to LEO Pharma

Up to €105 million

May 2015

Europe

Ipsen

Acquisition of OctreoPharm Sciences

Up to €50 million

May 2015

Europe

Lightlake Therapeutics

License of naloxone opioid overdose reversal treatment to Adapt Pharma

>$55 million

December 2014

Europe

Aseptix Health Sciences

License of antimicrobial technology to Ecolab

December 2014

Europe

Probiodrug

IPO Advisory

$30 million

October 2014

Europe

DBV Technologies

Global Offering Advisory

$116 million

October 2014

Europe

4-Antibody AG

Sale to Agenus

$40 million+ with $10mm upfront

January 2014

Europe

Almac

License to Chemotherapy Benefit Test for High Risk Breast Cancer

$9 million + milestones and royalties

November 2013

Europe

Correvio

Sale to Cardiome

19.9% shares + $12mm

November 2013

Europe

DBV Technologies

Financial Advisor in Private Placement

€29,900,000

November 2013

Europe

Sofgen

Sale of Nimodipine ANDA to ANI Pharmaceuticals

August 2013

Europe

Selexis

Sale of a recombinant protein royalty portfolio to Ligand

April 2013

Europe

Clinigen

Acquisition of EU rights to Vibativ from Theravance

$5mm + royalties

March 2013

Europe

Undisclosed

License of Rights of an OTC Product to a Large Pharma

March 2013

Europe

SpePharm

Joint Venture with Norgine

December 2012

Europe

Undisclosed

Licensing transaction to a large pharma in the pain area

October 2011

Europe

Undisclosed

Acquisition of global rights to a hospital antifungal product

July 2011

Europe

Explore Torreya's activities in other geographies: